Kailera Therapeutics, Inc.

NASDAQ: KLRA · Healthcare · Biotechnology

PublicHQ Waltham, MA · MiddlesexCIK 0002096997Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 52

v0.1 · 5/100 weight · pillars only

↑ market scale, workforce scale · ↓ listing tenure, filing timeliness

Methodology →

Revenue TTM

—

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

—

Employees

145

as of 2026-09-01

Market cap

$2.0B

as of 2026-09-01

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

No filed financials — private or non-XBRL filer.

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Kailera Therapeutics, Inc.’s financial profile?

Kailera Therapeutics, Inc. has no structured financials on file — private or non-XBRL filer.

Peers · Healthcare

Rapport Therapeutics, Inc. Common Stock——Hemab Therapeutics Holdings, Inc. Common Stock——Alamar Biosciences, Inc.——Generate Biomedicines, Inc.——Braveheart Bio, Inc.——Damora Therapeutics, Inc.——

Neighbors

Middlesex →

GE Vernova Inc.$38.1B65B Thermo Fisher Scientific Inc.$44.6B86A Analog Devices, Inc.$11.0B87A The TJX Companies, Inc.$60.4B85A Boston Scientific Corporation$20.1B88A Moderna, Inc.$1.9B52D

Key facts

CEORonald C. Renaud Jr.

SectorHealthcare

IndustryBiotechnology

HeadquartersWaltham, MA

ExchangeNASDAQ: KLRA

Employees145

IPO date2026-04-17

Latest filings

10-Q2026-08-12 8-K2026-08-12 10-Q2026-05-26 8-K2026-05-26 8-K2026-04-20

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.